82 related articles for article (PubMed ID: 36306196)
1. Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study.
Jeong H; Shin J; Jeong JH; Kim KP; Hong SM; Kim YI; Ryu JS; Ryoo BY; Yoo C
ESMO Open; 2021 Jun; 6(3):100119. PubMed ID: 33901869
[TBL] [Abstract][Full Text] [Related]
2. Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms.
Melhorn P; Mazal P; Wolff L; Popov P; Kretschmer-Chott E; Haug A; Mayerhoefer ME; Raderer M; Kiesewetter B
Endocr Relat Cancer; 2024 Mar; 31(3):. PubMed ID: 38214923
[TBL] [Abstract][Full Text] [Related]
3. Integrated Capecitabine-Temozolomide with Radioembolization for Liver-Dominant G2 NETs: Long-Term Outcomes of a Single-Institution Retrospective Study.
Soulen MC; Teitelbaum UR; Mick R; Eads J; Mondschein JI; Dagli M; van Houten D; Damjanov N; Schneider C; Cengel K; Metz DC
Cardiovasc Intervent Radiol; 2024 Jan; 47(1):60-68. PubMed ID: 38057498
[TBL] [Abstract][Full Text] [Related]
4. Risk Stratification of Pancreatic Neuroendocrine Neoplasms Based on Clinical, Pathological, and Molecular Characteristics.
Choi JH; Paik WH
J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36556070
[TBL] [Abstract][Full Text] [Related]
5. Metronomic Temozolomide (mTMZ) and Bevacizumab-The Safe and Effective Frontier for Treating Metastatic Neuroendocrine Tumors (NETs): A Single-Center Experience.
Ünal Ç; Sağlam S
Cancers (Basel); 2023 Dec; 15(23):. PubMed ID: 38067391
[TBL] [Abstract][Full Text] [Related]
6. Metronomic and metronomic-like therapies in neuroendocrine tumors - Rationale and clinical perspectives.
Lambrescu I; Fica S; Martins D; Spada F; Cella C; Bertani E; Rubino M; Gibelli B; Grana C; Bonomo G; Funicelli L; Ravizza D; Pisa E; Zerini D; Ungaro A; Fazio N;
Cancer Treat Rev; 2017 Apr; 55():46-56. PubMed ID: 28314176
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?
Lamarca A; Elliott E; Barriuso J; Backen A; McNamara MG; Hubner R; Valle JW
Cancer Treat Rev; 2016 Mar; 44():26-41. PubMed ID: 26855376
[TBL] [Abstract][Full Text] [Related]
8. Metronomic chemotherapy in patients with advanced neuroendocrine tumors: A single-center retrospective analysis.
Arrivi G; Spada F; Frassoni S; Bagnardi V; Laffi A; Rubino M; Gervaso L; Fazio N
J Neuroendocrinol; 2022 Oct; 34(10):e13189. PubMed ID: 36306196
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms.
Al-Toubah T; Morse B; Strosberg J
Oncologist; 2020 Jan; 25(1):e48-e52. PubMed ID: 31455747
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis.
Bongiovanni A; Liverani C; Foca F; Fausti V; Di Menna G; Mercatali L; De Vita A; Riva N; Calpona S; Miserocchi G; Spadazzi C; Cocchi C; Ibrahim T
Neuroendocrinology; 2021; 111(9):895-906. PubMed ID: 33221806
[TBL] [Abstract][Full Text] [Related]
11. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
Nicolini S; Bodei L; Bongiovanni A; Sansovini M; Grassi I; Ibrahim T; Monti M; Caroli P; Sarnelli A; Diano D; Di Iorio V; Grana CM; Cittanti C; Pieri F; Severi S; Paganelli G
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3260-3267. PubMed ID: 33604690
[TBL] [Abstract][Full Text] [Related]
12. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
Claringbold PG; Price RA; Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):561-9. PubMed ID: 23078020
[TBL] [Abstract][Full Text] [Related]
13. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
Ramirez RA; Beyer DT; Chauhan A; Boudreaux JP; Wang YZ; Woltering EA
Oncologist; 2016 Jun; 21(6):671-5. PubMed ID: 27226359
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
